Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas

Authors: KyuHo Lee, Kyoung-Bun Lee, Hae Yoen Jung, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Ja-June Jang

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

The Hippo pathway plays a vital role in liver regeneration and development by determining cellular lineage and regulating cell proliferation and apoptosis. In this study, we aimed to assess the role of the Hippo pathway in hepatic carcinogenesis and morphogenesis by examining Yes-associated protein 1 (YAP1) expression in the spectrum of hepatic carcinomas based on cellular lineage.

Methods

We examined 913 primary hepatic carcinomas, including hepatocellular carcinomas (HCCs), combined hepatocellular and cholangiocarcinomas (cHC-CCAs), intrahepatic cholangiocarcinomas (IHCCAs) and perihilar extrahepatic bile duct carcinomas (EHBCAs). Our study group was categorized into 8 disease groups, based on histological diagnosis and cytokeratin 19 (CK19) expression, and immunohistochemistry was used to detect and compare YAP1 expression levels between the groups. The eight disease groups we identified were: 1) CK19(−) HCC, 2) CK19(−) scirrhous HCC, 3) CK19(+) HCC, 4) stem cell feature of cHC-CCA, 5) classical cHC-CCA, 6) cholangiolocellular IHCCA, 7) non-cholangiolocellular IHCCA, and 8) EHBCA.

Results

Positive rates of YAP1 were the highest in the EHBCA group (21%). CK19(+) HCC and non-cholangiolocellular IHCCA groups also showed high expression levels (10% -11%), while the CK19 (−) HCC, CK19 (−) scirrhous HCC, cHC-CCA, and cholangiolocellular IHCCA groups showed low expression levels, ranging between 0% and 5%. Survival analysis, restricted to pT1 stage HCCs and IHCCAs, showed poor overall survival for YAP1(+) IHCCA patients (39 ± 17 vs. 109 ± 10 months, mean ± SD, log rank p-value 0.005). For HCCs, a trend of poor progression-free survival for YAP1(+) HCCs was observed (39 ± 18 vs. 81 ± 5 months, mean ± SD, log rank p-value 0.205)

Conclusions

YAP1 activation was more commonly found in CCAs than in pure HCCs. However, a differing pattern of YAP1 expression between cHC-CCAs and CK19(+) HCCs and the poor prognosis of YAP1 positive hepatic carcinomas suggests that YAP1 may have a preferential role in aggressive tumor behavior, rather than in the determination of cellular lineage in hepatic carcinomas.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232(1):10–24.CrossRefPubMedPubMedCentral Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232(1):10–24.CrossRefPubMedPubMedCentral
2.
go back to reference Lee JI, Lee JW, Kim JM, Kim JK, Chung HJ, Kim YS. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J Gastroenterol. 2012;18(34):4751–7.CrossRefPubMedPubMedCentral Lee JI, Lee JW, Kim JM, Kim JK, Chung HJ, Kim YS. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J Gastroenterol. 2012;18(34):4751–7.CrossRefPubMedPubMedCentral
4.
go back to reference Theise ND, Nakashima O, Park YN, Nakanuma Y. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010. Theise ND, Nakashima O, Park YN, Nakanuma Y. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010.
5.
go back to reference Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, et al. CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012;55(3):807–20.CrossRefPubMed Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, et al. CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012;55(3):807–20.CrossRefPubMed
6.
go back to reference Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–24.CrossRefPubMed Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–24.CrossRefPubMed
7.
go back to reference Zamboni G KG, Hruban RH. WHO classification of tumours. Pathology and Genetics of Tumours of the Digestive System. 3rd edn. Lyon: IARC Press; 2000. Zamboni G KG, Hruban RH. WHO classification of tumours. Pathology and Genetics of Tumours of the Digestive System. 3rd edn. Lyon: IARC Press; 2000.
8.
go back to reference Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci. 2015;22(2):94–100.CrossRefPubMed Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci. 2015;22(2):94–100.CrossRefPubMed
9.
go back to reference Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014;64(7):935–50.CrossRefPubMed Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014;64(7):935–50.CrossRefPubMed
10.
go back to reference Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, et al. Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54(5):1707–17.CrossRefPubMed Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, et al. Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54(5):1707–17.CrossRefPubMed
12.
go back to reference Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324–38.CrossRefPubMedPubMedCentral Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324–38.CrossRefPubMedPubMedCentral
13.
go back to reference Nguyen Q, Anders RA, Alpini G, Bai H. Yes-associated protein in the liver: regulation of hepatic development, repair, cell fate determination and tumorigenesis. Dig Liver Dis. 2015;47(10):826–35.CrossRefPubMed Nguyen Q, Anders RA, Alpini G, Bai H. Yes-associated protein in the liver: regulation of hepatic development, repair, cell fate determination and tumorigenesis. Dig Liver Dis. 2015;47(10):826–35.CrossRefPubMed
14.
go back to reference Hu XB, Xin Y, Xiao YP, Zhao J. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathology & Oncology Research. 2014;20(4):805–11.CrossRef Hu XB, Xin Y, Xiao YP, Zhao J. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathology & Oncology Research. 2014;20(4):805–11.CrossRef
15.
go back to reference Li M, Lu J, Zhang F, Li H, Zhang B, Wu X, et al. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer Lett. 2014;355(2):201–9.CrossRefPubMed Li M, Lu J, Zhang F, Li H, Zhang B, Wu X, et al. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer Lett. 2014;355(2):201–9.CrossRefPubMed
16.
go back to reference Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, et al. Yes-associated protein up-regulates jagged-1 and activates the notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144(7):1530–42. e1512CrossRefPubMedPubMedCentral Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, et al. Yes-associated protein up-regulates jagged-1 and activates the notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144(7):1530–42. e1512CrossRefPubMedPubMedCentral
17.
go back to reference Sun ZQ, Xu RW, Li XY, Ren WG, Ou CL, Wang QS, et al. Prognostic value of yes-associated protein 1 (YAP1) in various cancers: a meta-analysis. PLoS One. 2015;10(8):e0135119.CrossRefPubMedPubMedCentral Sun ZQ, Xu RW, Li XY, Ren WG, Ou CL, Wang QS, et al. Prognostic value of yes-associated protein 1 (YAP1) in various cancers: a meta-analysis. PLoS One. 2015;10(8):e0135119.CrossRefPubMedPubMedCentral
18.
go back to reference Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013;493(7430):106–10.CrossRefPubMed Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013;493(7430):106–10.CrossRefPubMed
19.
go back to reference Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRefPubMed Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRefPubMed
20.
go back to reference Japan LCSGo. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 1989;19(1):98–129. Japan LCSGo. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 1989;19(1):98–129.
21.
go back to reference Yimlamai D, Fowl BH, Camargo F. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63(6):1491–501.CrossRefPubMedPubMedCentral Yimlamai D, Fowl BH, Camargo F. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63(6):1491–501.CrossRefPubMedPubMedCentral
22.
go back to reference Yimlamai D, Christodoulou C, Galli Giorgio G, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324–38.CrossRefPubMedPubMedCentral Yimlamai D, Christodoulou C, Galli Giorgio G, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324–38.CrossRefPubMedPubMedCentral
23.
go back to reference Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125(7):1253–67.CrossRefPubMedPubMedCentral Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125(7):1253–67.CrossRefPubMedPubMedCentral
24.
go back to reference Li X, Tao J, Cigliano A, Sini M, Calderaro J, Azoulay D, et al. Co-activation of PIK3CA and yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 2015;6(12):10102–15.CrossRefPubMedPubMedCentral Li X, Tao J, Cigliano A, Sini M, Calderaro J, Azoulay D, et al. Co-activation of PIK3CA and yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 2015;6(12):10102–15.CrossRefPubMedPubMedCentral
25.
go back to reference Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088–96.CrossRefPubMed Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088–96.CrossRefPubMed
26.
go back to reference Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, et al. activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014;147(3):690–701.CrossRefPubMedPubMedCentral Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, et al. activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014;147(3):690–701.CrossRefPubMedPubMedCentral
27.
go back to reference Kim GJ, Kim H, Park YN. Increased expression of yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One. 2013;8(9):e75449.CrossRefPubMedPubMedCentral Kim GJ, Kim H, Park YN. Increased expression of yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One. 2013;8(9):e75449.CrossRefPubMedPubMedCentral
28.
go back to reference Li H, Wang SH, Wang GY, Zhang ZG, Wu XC, Zhang T, et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. Dig Surg. 2014;31(6):468–78.CrossRefPubMed Li H, Wang SH, Wang GY, Zhang ZG, Wu XC, Zhang T, et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. Dig Surg. 2014;31(6):468–78.CrossRefPubMed
29.
Metadata
Title
The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas
Authors
KyuHo Lee
Kyoung-Bun Lee
Hae Yoen Jung
Nam-Joon Yi
Kwang-Woong Lee
Kyung-Suk Suh
Ja-June Jang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3431-1

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine